Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $4.65 million versus the consensus estimate of $6.18 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.